Mesenchymal Stem Cell (MSC)-Based Drug Delivery into the Brain across the Blood-Brain Barrier

被引:11
|
作者
Tashima, Toshihiko [1 ]
机构
[1] Tashima Labs Arts & Sci, 1239-5 Toriyama Cho,Kohoku Ku, Yokohama 2220035, Japan
关键词
the blood-brain barrier; mesenchymal stem cell-based drug delivery; transmembrane drug delivery; PATHOPHYSIOLOGY; INHIBITOR;
D O I
10.3390/pharmaceutics16020289
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
At present, stem cell-based therapies using induced pluripotent stem cells (iPSCs) or mesenchymal stem cells (MSCs) are being used to explore the potential for regenerative medicine in the treatment of various diseases, owing to their ability for multilineage differentiation. Interestingly, MSCs are employed not only in regenerative medicine, but also as carriers for drug delivery, homing to target sites in injured or damaged tissues including the brain by crossing the blood-brain barrier (BBB). In drug research and development, membrane impermeability is a serious problem. The development of central nervous system drugs for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, remains difficult due to impermeability in capillary endothelial cells at the BBB, in addition to their complicated pathogenesis and pathology. Thus, intravenously or intraarterially administered MSC-mediated drug delivery in a non-invasive way is a solution to this transendothelial problem at the BBB. Substances delivered by MSCs are divided into artificially included materials in advance, such as low molecular weight compounds including doxorubicin, and expected protein expression products of genetic modification, such as interleukins. After internalizing into the brain through the fenestration between the capillary endothelial cells, MSCs release their cargos to the injured brain cells. In this review, I introduce the potential and advantages of drug delivery into the brain across the BBB using MSCs as a carrier that moves into the brain as if they acted of their own will.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Drug transport across the blood-brain barrier
    Fricker, G
    PHARMACOKINETIC CHALLENGES IN DRUG DISCOVERY, 2002, 37 : 139 - 154
  • [32] Drug transport across the blood-brain barrier
    Pardridge, William M.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 (11): : 1959 - 1972
  • [33] Advanced Blood-Brain Barrier Drug Delivery
    Pardridge, William M.
    PHARMACEUTICS, 2023, 15 (01)
  • [34] Breaching the Blood-Brain Barrier for Drug Delivery
    Bell, Robert D.
    Ehlers, Michael D.
    NEURON, 2014, 81 (01) : 1 - 3
  • [35] Drug delivery via the blood-brain barrier
    Edwards, RH
    NATURE NEUROSCIENCE, 2001, 4 (03) : 221 - 222
  • [36] Drug delivery through the blood-brain barrier
    Tamai, I
    Tsuji, A
    ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (03) : 401 - 424
  • [37] Drug delivery to brain tumors and the problem of the blood-brain barrier
    Smith, Quentin R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [38] Blood-brain barrier and laser technology for drug brain delivery
    Semyachkina-Glushkovskaya, Oxana V.
    Abdurashitov, Arkady S.
    Saranceva, Elena I.
    Borisova, Eketerina G.
    Shirokov, Alexander A.
    Navolokin, Nikita V.
    JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES, 2017, 10 (05)
  • [39] Nanoparticles for brain drug delivery - overcoming the blood-brain barrier
    Chaparro, C.
    Cavaco, M.
    Borges, J. P.
    Castanho, M.
    Soares, P.
    Neves, V.
    FEBS OPEN BIO, 2022, 12 : 29 - 30
  • [40] Curcumin Oligosaccharides (Gluco-oligosaccharides) Penetrate the Blood-Brain Barrier in Mouse Brain: Glycoside (Polysaccharide) Modification Approach for Brain Drug Delivery Across the Blood-Brain Barrier and Tumor Drug Delivery
    Hamada, Hiroki
    Nakayama, Takahiro
    Shimoda, Kei
    Matsuura, Nobuyasu
    Hamada, Hatsuyuki
    Iwaki, Takafumi
    Kiriake, Yuya
    Saikawa, Tomohiro
    NATURAL PRODUCT COMMUNICATIONS, 2020, 15 (11)